MA39247B1 - 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque - Google Patents

2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque

Info

Publication number
MA39247B1
MA39247B1 MA39247A MA39247A MA39247B1 MA 39247 B1 MA39247 B1 MA 39247B1 MA 39247 A MA39247 A MA 39247A MA 39247 A MA39247 A MA 39247A MA 39247 B1 MA39247 B1 MA 39247B1
Authority
MA
Morocco
Prior art keywords
obesity
treatment
diabetes mellitus
guanidinophenyl
hyperlipidemia
Prior art date
Application number
MA39247A
Other languages
English (en)
Other versions
MA39247A1 (fr
Inventor
Minoru Sasaki
Keiko Kakegawa
Fumiaki Kikuchi
Zenichi Ikeda
Yoichi Nishikawa
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA39247A1 publication Critical patent/MA39247A1/fr
Publication of MA39247B1 publication Critical patent/MA39247B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne un composé hétérocyclique fusionné ayant une action inhibitrice de l'entéropeptidase et une utilisation du composé en tant que médicament pour le traitement ou la prophylaxie de l'obésité, du diabète sucré, etc.. Plus particulièrement, elle concerne un composé représenté par la formule suivante (i) : dans laquelle chaque symbole est tel que défini dans la description, ou un sel de celui-ci et l'utilisation du composé en tant que médicament pour le traitement ou la prophylaxie de l'obésité, du diabète sucré, etc..
MA39247A 2014-02-13 2015-02-12 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque MA39247B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014025944 2014-02-13
PCT/JP2015/000640 WO2015122188A1 (fr) 2014-02-13 2015-02-12 Composé hétérocyclique

Publications (2)

Publication Number Publication Date
MA39247A1 MA39247A1 (fr) 2017-11-30
MA39247B1 true MA39247B1 (fr) 2018-04-30

Family

ID=52589730

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39247A MA39247B1 (fr) 2014-02-13 2015-02-12 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque

Country Status (22)

Country Link
US (2) US9428470B2 (fr)
EP (1) EP3105228B1 (fr)
JP (1) JP6458054B2 (fr)
KR (1) KR20160113299A (fr)
CN (1) CN106170487A (fr)
AR (1) AR099399A1 (fr)
AU (1) AU2015216439A1 (fr)
BR (1) BR112016018548A2 (fr)
CA (1) CA2939675A1 (fr)
CL (1) CL2016002023A1 (fr)
CR (1) CR20160368A (fr)
EA (1) EA201691624A1 (fr)
EC (1) ECSP16067163A (fr)
IL (1) IL247018A0 (fr)
MA (1) MA39247B1 (fr)
MX (1) MX2016010561A (fr)
PE (1) PE20161396A1 (fr)
PH (1) PH12016501614A1 (fr)
SG (1) SG11201606176YA (fr)
TW (1) TW201609677A (fr)
UY (1) UY35995A (fr)
WO (1) WO2015122188A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2975023T (lt) 2013-03-13 2018-08-10 Takeda Pharmaceutical Company Limited Guanidinbenzoinės rūgšties esterio junginys
KR102304113B1 (ko) 2014-02-10 2021-09-24 프레드 헛친슨 켄서 리서치 센터 심장마비 및 허혈성 손상의 할로겐 치료
WO2015123437A1 (fr) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
JP2018080109A (ja) * 2015-03-16 2018-05-24 武田薬品工業株式会社 治療剤
JP6634070B2 (ja) * 2015-03-27 2020-01-22 武田薬品工業株式会社 縮合複素環化合物
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
CN111542511A (zh) 2017-11-02 2020-08-14 宇部兴产株式会社 蛋白分解酶的双头型抑制剂
UA126099C2 (uk) 2018-05-09 2022-08-10 ЕлДжи КЕМ, ЛТД. Сполука, яка виявляє інгібувальну активність відносно ентеропептидази
JP6773938B2 (ja) * 2018-08-27 2020-10-21 株式会社スコヒアファーマ 安息香酸エステル化合物
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation
US12268672B2 (en) 2018-10-23 2025-04-08 Japan Science And Technology Agency PPARδ activator
WO2021013742A1 (fr) 2019-07-19 2021-01-28 Janssen Pharmaceutica Nv Dérivés de [1,2,4]triazolo[1,5-a]pyridinyle 5,8-disubstitués et d'imidazo[1,2-a]pyridine 5,8-disubstitués utiles en tant qu'inhibiteurs de l'entéropeptidase
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
CN114929246A (zh) * 2019-11-04 2022-08-19 法拉第制药公司 碘化物化合物用于治疗和预防化学疗法相关的恶病质和心脏毒性的用途
WO2021166899A1 (fr) * 2020-02-17 2021-08-26 宇部興産株式会社 Médicament contenant un inhibiteur de protéase gastrique destiné à être utilisé en association avec un mimétique d'incrétine
CN111803652B (zh) * 2020-08-04 2021-09-14 南通康是美生物科技有限公司 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5289640A (en) 1976-01-21 1977-07-27 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
JPS5753454A (en) 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
US5116985A (en) 1989-12-28 1992-05-26 Snow Brand Milk Products Co., Ltd. Isoquinoline derivatives and salts thereof
JP2886586B2 (ja) 1989-12-28 1999-04-26 雪印乳業株式会社 新規グアニジノ安息香酸誘導体及びその酸付加塩
JPH0446148A (ja) 1990-06-08 1992-02-17 Asahi Chem Ind Co Ltd ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤
JPH06192085A (ja) 1992-08-31 1994-07-12 Yuji Inada ダニアレルギー治療剤
WO1994013631A1 (fr) 1992-12-10 1994-06-23 Teikoku Chemical Industries Co., Ltd. Derive d'acide proprionique
JPH0753500A (ja) 1993-08-16 1995-02-28 Sanwa Kagaku Kenkyusho Co Ltd グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JPH0848664A (ja) 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc 新規なグアニジノ安息香酸エステル誘導体
WO1997010224A1 (fr) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Composes de benzoxazepine, leur production et leur utilisation en tant qu'agent d'abaissement des niveaux de lipides
JPH09124571A (ja) 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
US6388122B1 (en) 1996-04-10 2002-05-14 Ono Pharmaceutical Co., Ltd. Tryptase inhibitor and novel guanidino derivatives
JPH10101556A (ja) 1996-09-27 1998-04-21 Ono Pharmaceut Co Ltd ファクターｄ阻害剤
JPH10251239A (ja) 1997-03-14 1998-09-22 Mochida Pharmaceut Co Ltd 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体
JPH10306025A (ja) 1997-05-07 1998-11-17 Touin Yokohama Univ 花粉プロテアーゼ阻害剤
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
PL376733A1 (pl) 2002-11-01 2006-01-09 Takeda Pharmaceutical Company Limited Środek do zapobiegania lub leczenia neuropatii
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (fr) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Derives d'imidazole, leur procede de production et d'utilisation
EP1630152A4 (fr) 2003-05-30 2009-09-23 Takeda Pharmaceutical Compose cyclique condense
EP1669352A4 (fr) 2003-09-30 2008-12-17 Takeda Pharmaceutical Derive thiazoline et utilisation
EP1695961A4 (fr) 2003-12-17 2007-10-24 Takeda Pharmaceutical Derives d'uree, processus de production correspondant et utilisation
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
EP1726580A4 (fr) 2004-03-15 2008-02-13 Takeda Pharmaceutical Derive de l'acide aminophnylpropano
EP1731505B1 (fr) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Dérivés de l'acide alkoxyphénylpropanoïque
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7671057B2 (en) 2004-11-08 2010-03-02 Ono Pharmaceutical Co., Ltd. Therapeutic agent for type II diabetes comprising protease-inhibiting compound
EP1843819A2 (fr) 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Procedes de reduction de la graisse corporelle
US20080274945A1 (en) 2004-11-26 2008-11-06 N.V. Nutricia Infant Nutrition With Protease Inhibitor
EP2308839B1 (fr) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Composés hétérocycliques condensés
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
CA2617969A1 (fr) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Agent therapeutique pour le diabete
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2007208495A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
ES2379661T3 (es) 2006-06-27 2012-04-30 Takeda Pharmaceutical Company Limited Compuestos cíclicos condensados
JP5306818B2 (ja) 2006-10-18 2013-10-02 武田薬品工業株式会社 縮合複素環化合物
US8410087B2 (en) 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
EP2128138A1 (fr) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Composé de pyrazole
CA2677736A1 (fr) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Composes a cycles fusionnes utiles en tant qu'agonistes partiels de ppar-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
WO2008156757A1 (fr) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Composés d'indazole permettant d'activer la glucokinase
EP2225261B1 (fr) 2007-12-03 2016-03-09 Obe Therapy Biotechnology Inhibiteurs boropeptidiques de l'entérokinase et leurs utilisations dans le traitement de l'obésité, de la surcharge pondérale et/ou des maladies associées avec un métabolisme anormal des lipides
CN102822154B (zh) * 2009-12-07 2016-06-01 味之素株式会社 杂芳基羧酸酯衍生物
WO2012169579A1 (fr) 2011-06-07 2012-12-13 味の素株式会社 Dérivé d'ester d'acide carboxylique hétérocyclique
PH12014500573A1 (en) 2011-09-15 2014-04-14 Astellas Pharma Inc Guanidinobenzoic acid compound
US10398762B2 (en) 2012-01-03 2019-09-03 Oramed Ltd. Methods and compositions for treating diabetes
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
EP2941267B1 (fr) 2013-01-03 2022-11-16 Oramed Ltd. Compositions pour l'utilisation dans le traitement de la stéatopathie hépatique non alcoolique
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
LT2975023T (lt) 2013-03-13 2018-08-10 Takeda Pharmaceutical Company Limited Guanidinbenzoinės rūgšties esterio junginys
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
DK3046584T3 (en) 2013-09-16 2017-10-02 Astrazeneca Ab THERAPEUTIC POLYMER NANOPARTICLES AND PROCEDURES FOR PREPARING AND USING THEREOF
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound

Also Published As

Publication number Publication date
US9428470B2 (en) 2016-08-30
JP2017505823A (ja) 2017-02-23
MA39247A1 (fr) 2017-11-30
AU2015216439A1 (en) 2016-08-11
PE20161396A1 (es) 2017-01-10
CL2016002023A1 (es) 2017-03-24
KR20160113299A (ko) 2016-09-28
UY35995A (es) 2015-08-31
US10023544B2 (en) 2018-07-17
JP6458054B2 (ja) 2019-01-23
CA2939675A1 (fr) 2015-08-20
CN106170487A (zh) 2016-11-30
EP3105228B1 (fr) 2018-09-26
US20160347724A1 (en) 2016-12-01
TW201609677A (zh) 2016-03-16
EA201691624A1 (ru) 2017-05-31
SG11201606176YA (en) 2016-08-30
EP3105228A1 (fr) 2016-12-21
AR099399A1 (es) 2016-07-20
PH12016501614A1 (en) 2017-02-06
CR20160368A (es) 2016-12-01
BR112016018548A2 (pt) 2019-01-15
US20150225354A1 (en) 2015-08-13
MX2016010561A (es) 2016-11-16
WO2015122188A1 (fr) 2015-08-20
IL247018A0 (en) 2016-09-29
ECSP16067163A (es) 2017-10-31

Similar Documents

Publication Publication Date Title
MA39247B1 (fr) 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque
MA39246A1 (fr) Composé hétérocyclique fusionné
MA39688A (fr) Composés hétéroaryle pour le traitement de maladies ophtalmiques
WO2018182051A8 (fr) Inhibiteurs d'ip6k
MA52948B1 (fr) Composés
MA40060A (fr) Composés hétérocycliques et leur utilisation en tant qu'inhibiteurs gamma-t du récepteur orphelin apparenté aux récepteurs des rétinoïdes (ror) )
MA35085B1 (fr) Procede de traitement d'une nephropathie induite par les produits de contraste
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA38472B1 (fr) Composé peptidique
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
MA39427B1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
MA34713B1 (fr) Compose bicyclique
MA35623B1 (fr) Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA40302B1 (fr) Dérivés de carbazole
MA33280B1 (fr) Preparation solide
MA38358A1 (fr) Formulations de composés organiques
MA32283B1 (fr) Composes cycliques condenses et utilisation de ceux-ci
BR112016028037A2 (pt) Novos compostos
MX2023010303A (es) Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol.
WO2018194181A8 (fr) Composés hétérocycliques utiles en tant que modulateurs des récepteurs de l'acétylcholine
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain